ANIMALCARE GROUP PLC
("Animalcare" or the "Company")
CORRECTIVE ANNOUNCEMENT IN RELATION TO THE COMPANY'S H1 2022 INTERIM RESULTS
20 October 2022. Animalcare Group plc (AIM: ANCR), the international animal health business, notes that the Interim Results for the six months ended 30 June 2022 ("H1 2022") published by the Company on 27 September 2022 incorrectly stated the following for H1 2022:
· "Investment in Joint Ventures" should have stated £1,430,000 as at 30 June 2022 (versus £78,000 as published on 27 September 2022);
· "Total Non-Current Assets" should have stated £85,434,000 as at 30 June 2022 (versus £84,082,000);
· "Total assets" should have stated £117,886,000 as at 30 June 2022 (versus £116,534,000); and
· "Net assets" should have stated £80,154,000 as at 30 June 2022 (versus £78,802,000).
Other than the items listed above, all the financial information contained in the Interim Results announcement published by the Company on 27 September 2022 remains accurate.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
Enquiries:
| Animalcare Group plc Chris Brewster, Chief Financial Officer | +44 (0)1904 487 687 communications@animalcaregroup.com |
| Stifel Nicolaus Europe Limited (Nominated Adviser & Joint Broker) Ben Maddison Nicholas Harland Nick Adams
| +44 (0)20 7710 7600 |
| Panmure Gordon (Joint Broker) Corporate Finance: Freddy Crossley/Emma Earl Corporate Broking: Rupert Dearden
| +44 (0)20 7886 2500 |
About Animalcare
Animalcare Group plc is a UK AIM-listed international development-focused veterinary sales and marketing organisation. Animalcare operates in seven countries and exports to approximately 40 countries in Europe and worldwide. The Group is focused on bringing new and innovative products to market through its own development pipeline, partnerships and via acquisition.
For more information about Animalcare, please visit www.animalcaregroup.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
